Clene Reports Q3 2024 Financial Results and Updates on CNM-Au8 Programs
Clene Inc. reports Q3 2024 financial results and updates on CNM-Au8 programs, demonstrating commitment to ALS treatment innovation. Visit www.Clene.com for more information. Investors can track CLNN updates at https://ibn.fm/CLNN.
This news highlights Clene's advancements in ALS treatment innovation and financial progress, showcasing the company's commitment to neurodegenerative disease research. Investors can track CLNN updates at https://ibn.fm/CLNN.